“Pipeline”

41 result(s)
Drug Pipeline
Promising Treatments for Alopecia Areata in the Pipeline
New Treatments for Alopecia Areata on the Horizon More
Briefing
Icon of an infusion bag, overlaying a rising line graph
Specialty
Managing the MS Cost Challenge
Multiple Sclerosis is a $19 billion market worldwide, and the third most expensive specialty drug spend category. Recently approved Ocrevus is likely to add to cost of treatment... More
Briefing
Drug Pipeline
Keeping an Eye on the Drug Pipeline
New Drugs for Ophthalmic Disorders on the Horizon More
Briefing
Health Equity
Marketplace Trends Shape Specialty Landscape
... More
Briefing
Specialty
Three Major Challenges Facing Gene Therapy
The Top Challenges Facing Gene Therapy Today More
Briefing
Drug Pipeline
A Q2 2022 Look at Projected Gene Therapies and Approval Timelines
A Q2 2022 Look at Projected Gene Therapies and FDA Approval Timelines More
Briefing
Cost Management
Strategy and Balance: Managing Costs for Pulmonary Arterial Hypertension
Managing Treatment Costs for Pulmonary Arterial Hypertension More
Briefing
Cost Management
A Breath of Fresh Air for Patients with Pulmonary Arterial Hypertension
New Dry Powder Inhalation Therapies for PAH in Pipeline More
Briefing
Specialty
The Role of Biosimilars in Lowering Specialty Costs
Biosimilars Can Be Part of a Strategy to Lower Specialty Drug Costs More
Briefing
Drug Pipeline
Treatment Options Expand in Robust Gene Therapy Pipeline
New Gene Therapies for Sickle Cell Disease, Hemophilia on the Horizon More
Briefing